Vaccination against helminth parasites - The ultimate challenge for vaccinologists?

Rick M. Maizels, Martin J. Holland, Franco H. Falcone, Xingxing Zang, Maria Yazdanbakhsh

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Helminths are multicellular pathogens which infect vast numbers of human and animal hosts, causing widspread chronic disease and morbidity. Vaccination against these parasites requires more than identification of effective target antigens, because without understanding the immunology of the host-parasite relationship, ineffective immune mechanisms may be invoked, and there is a danger of amplifying immunopathogenic responses. The fundamental features of the immune response to helminths are therefore summarised in the context of vaccines to helminth parasites. The contention between type-1 and type-2 responses is a central issue in helminth infections, which bias the immune system strongly to the type-2 pathway. Evidence from both human and experimental animal infections indicates that both lineages contribute to immunity in differing circumstances, and that a balanced response leads to the most favourable outcome. A diversity of immune mechanisms can be brought to bear on various helminth species, ranging from antibody-independent macrophages, antibody-dependent granulocyte killing, and non-lymphoid actions, particularly in the gut. This diversity is highlighted by analysis of rodent infections, particularly in comparisons of cytokine-depleted and gene-targeted animals. This knowledge of protective mechanisms needs to be combined with a careful choice of parasite antigens for vaccines. Many existing candidates have been selected with host antibodies, rather than T-cell responses, and include a preponderance of highly conserved proteins with similarities to mammalian or invertebrate antigens. Advantage has yet to be taken of parasite genome projects, or of directed searches for novel, parasite-specific antigens and targets expressed only by infective stages and not mature forms which may generate immunopathology. With advances under way in parasite genomics and new vaccine delivery systems offering more rapid assessment and development, there are now excellent opportunities for new antihelminth vaccines.

Original languageEnglish (US)
Pages (from-to)125-147
Number of pages23
JournalImmunological Reviews
Volume171
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Helminths
Parasites
Vaccination
Vaccines
Antigens
Antibodies
Infection
Host-Parasite Interactions
Invertebrates
Genomics
Allergy and Immunology
Granulocytes
Immune System
Immunity
Rodentia
Chronic Disease
Macrophages
Genome
Cytokines
Morbidity

ASJC Scopus subject areas

  • Immunology

Cite this

Vaccination against helminth parasites - The ultimate challenge for vaccinologists? / Maizels, Rick M.; Holland, Martin J.; Falcone, Franco H.; Zang, Xingxing; Yazdanbakhsh, Maria.

In: Immunological Reviews, Vol. 171, 1999, p. 125-147.

Research output: Contribution to journalArticle

Maizels, Rick M. ; Holland, Martin J. ; Falcone, Franco H. ; Zang, Xingxing ; Yazdanbakhsh, Maria. / Vaccination against helminth parasites - The ultimate challenge for vaccinologists?. In: Immunological Reviews. 1999 ; Vol. 171. pp. 125-147.
@article{8588a7d02b4e45cc86e1f57cb82cf736,
title = "Vaccination against helminth parasites - The ultimate challenge for vaccinologists?",
abstract = "Helminths are multicellular pathogens which infect vast numbers of human and animal hosts, causing widspread chronic disease and morbidity. Vaccination against these parasites requires more than identification of effective target antigens, because without understanding the immunology of the host-parasite relationship, ineffective immune mechanisms may be invoked, and there is a danger of amplifying immunopathogenic responses. The fundamental features of the immune response to helminths are therefore summarised in the context of vaccines to helminth parasites. The contention between type-1 and type-2 responses is a central issue in helminth infections, which bias the immune system strongly to the type-2 pathway. Evidence from both human and experimental animal infections indicates that both lineages contribute to immunity in differing circumstances, and that a balanced response leads to the most favourable outcome. A diversity of immune mechanisms can be brought to bear on various helminth species, ranging from antibody-independent macrophages, antibody-dependent granulocyte killing, and non-lymphoid actions, particularly in the gut. This diversity is highlighted by analysis of rodent infections, particularly in comparisons of cytokine-depleted and gene-targeted animals. This knowledge of protective mechanisms needs to be combined with a careful choice of parasite antigens for vaccines. Many existing candidates have been selected with host antibodies, rather than T-cell responses, and include a preponderance of highly conserved proteins with similarities to mammalian or invertebrate antigens. Advantage has yet to be taken of parasite genome projects, or of directed searches for novel, parasite-specific antigens and targets expressed only by infective stages and not mature forms which may generate immunopathology. With advances under way in parasite genomics and new vaccine delivery systems offering more rapid assessment and development, there are now excellent opportunities for new antihelminth vaccines.",
author = "Maizels, {Rick M.} and Holland, {Martin J.} and Falcone, {Franco H.} and Xingxing Zang and Maria Yazdanbakhsh",
year = "1999",
doi = "10.1111/j.1600-065X.1999.tb01345.x",
language = "English (US)",
volume = "171",
pages = "125--147",
journal = "Immunological Reviews",
issn = "0105-2896",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Vaccination against helminth parasites - The ultimate challenge for vaccinologists?

AU - Maizels, Rick M.

AU - Holland, Martin J.

AU - Falcone, Franco H.

AU - Zang, Xingxing

AU - Yazdanbakhsh, Maria

PY - 1999

Y1 - 1999

N2 - Helminths are multicellular pathogens which infect vast numbers of human and animal hosts, causing widspread chronic disease and morbidity. Vaccination against these parasites requires more than identification of effective target antigens, because without understanding the immunology of the host-parasite relationship, ineffective immune mechanisms may be invoked, and there is a danger of amplifying immunopathogenic responses. The fundamental features of the immune response to helminths are therefore summarised in the context of vaccines to helminth parasites. The contention between type-1 and type-2 responses is a central issue in helminth infections, which bias the immune system strongly to the type-2 pathway. Evidence from both human and experimental animal infections indicates that both lineages contribute to immunity in differing circumstances, and that a balanced response leads to the most favourable outcome. A diversity of immune mechanisms can be brought to bear on various helminth species, ranging from antibody-independent macrophages, antibody-dependent granulocyte killing, and non-lymphoid actions, particularly in the gut. This diversity is highlighted by analysis of rodent infections, particularly in comparisons of cytokine-depleted and gene-targeted animals. This knowledge of protective mechanisms needs to be combined with a careful choice of parasite antigens for vaccines. Many existing candidates have been selected with host antibodies, rather than T-cell responses, and include a preponderance of highly conserved proteins with similarities to mammalian or invertebrate antigens. Advantage has yet to be taken of parasite genome projects, or of directed searches for novel, parasite-specific antigens and targets expressed only by infective stages and not mature forms which may generate immunopathology. With advances under way in parasite genomics and new vaccine delivery systems offering more rapid assessment and development, there are now excellent opportunities for new antihelminth vaccines.

AB - Helminths are multicellular pathogens which infect vast numbers of human and animal hosts, causing widspread chronic disease and morbidity. Vaccination against these parasites requires more than identification of effective target antigens, because without understanding the immunology of the host-parasite relationship, ineffective immune mechanisms may be invoked, and there is a danger of amplifying immunopathogenic responses. The fundamental features of the immune response to helminths are therefore summarised in the context of vaccines to helminth parasites. The contention between type-1 and type-2 responses is a central issue in helminth infections, which bias the immune system strongly to the type-2 pathway. Evidence from both human and experimental animal infections indicates that both lineages contribute to immunity in differing circumstances, and that a balanced response leads to the most favourable outcome. A diversity of immune mechanisms can be brought to bear on various helminth species, ranging from antibody-independent macrophages, antibody-dependent granulocyte killing, and non-lymphoid actions, particularly in the gut. This diversity is highlighted by analysis of rodent infections, particularly in comparisons of cytokine-depleted and gene-targeted animals. This knowledge of protective mechanisms needs to be combined with a careful choice of parasite antigens for vaccines. Many existing candidates have been selected with host antibodies, rather than T-cell responses, and include a preponderance of highly conserved proteins with similarities to mammalian or invertebrate antigens. Advantage has yet to be taken of parasite genome projects, or of directed searches for novel, parasite-specific antigens and targets expressed only by infective stages and not mature forms which may generate immunopathology. With advances under way in parasite genomics and new vaccine delivery systems offering more rapid assessment and development, there are now excellent opportunities for new antihelminth vaccines.

UR - http://www.scopus.com/inward/record.url?scp=0032719191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032719191&partnerID=8YFLogxK

U2 - 10.1111/j.1600-065X.1999.tb01345.x

DO - 10.1111/j.1600-065X.1999.tb01345.x

M3 - Article

C2 - 10582168

AN - SCOPUS:0032719191

VL - 171

SP - 125

EP - 147

JO - Immunological Reviews

JF - Immunological Reviews

SN - 0105-2896

ER -